The CDC specifically recommended that expectant mothers 32 to 36 weeks into their pregnancy receive the shot, Pfizer's ...

The Food and Drug Administration approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S. The company's ...

A Pfizer Inc. PFE, -0.48% vaccine designed to protect babies from respiratory syncytial virus, or RSV, got a green light Monday from the U.S. Food and Drug Administration — a key milestone for ...

The Food and Drug Administration (FDA) has approved the first vaccine for pregnant women to prevent RSV in infants, the agency announced on Monday. Abrysvo has been approved as a maternal vaccine to ...

The U.S. Centers for Disease Control and Prevention have recommended the first-ever vaccine designed to protect infants from ...

The Food and Drug Administration approved Abrysvo, Pfizer’s respiratory syncytial virus (RSV) vaccine, for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD ...

The U.S. Food and Drug Administration on Monday approved the first vaccine that protects newborns from respiratory syncytial virus, known as RSV. The vaccine, made by Pfizer, is given to mothers ...

The shot will help shield newborns from RSV in the early months of life, when they're especially vulnerable to severe illness ...

An advisory panel for the U.S. Centers of Disease Control and Prevention on Friday recommended that a vaccine for respiratory syncytial virus, or RSV, be given during pregnancy, providing an extra ...

The US Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their ...